The 6th annual Obesity and Nash Summit focusing on drug development
Nordic Bioscience looks forward to participating in the 6th Annual Obesity and NASH drug development summit.
"Uniting industry experts dedicated to accelerating the frontier of therapeutic development in metabolic syndrome, the 6th Obesity & NASH Drug Development Summit (previously the NASH Summit), is the definitive industry forum sharing cross-industry insight to drive holistic approaches to drug development in metabolic syndrome." (6th Obesity & NASH Drug Development Summit 2022)
As the creators of the worldwide renowned PRO-C3 biomarker assay known for its proven utility in liver and diabetes clinical trials, we are excited about this important event in the Obesity and NASH field.
Morten Karsdal, CEO of Nordic Bioscience, will give a presentation at the conference, titled "The first true fibrosis resolution biomarker in NASH
Extracellular matrix remodeling is the common denominator in all fibrotic disorders
Targeting tissue formation and tissue degradation reveals anti-fibrogenesis or fibrosis resolution
Quantifying tissue remodeling shows different modes of action for reversing liver fibrosis
